Drugs / Fecal Microbiota
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06058520 | Oct 2023 → Sep 2026 expected | hidradenitis suppurativa | University of Minnesota | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02256592 | Oct 2014 → Mar 2017 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05917379 | Oct 2023 → Apr 2025 | anxiety, cognitive impairment with or without cerebellar ataxia, depressive disorder, insomnia | Peking University Sixth Hospital | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04132427 | Sep 2019 → Mar 2022 | Pitt-Hopkins syndrome | Arizona State University | Completed | No outcome recorded |
| Phase 2 | NCT03281044 | Oct 2018 → Mar 2020 | major depressive disorder | Psychiatric Hospital of the University of Basel | Terminated | No outcome recorded |
| Phase 2 | NCT02127398 | Apr 2016 → May 2026 overdue | Clostridium difficile colitis | Duke University | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02686645 | Dec 2016 → Dec 2021 | Clostridium difficile colitis | Queen Elizabeth II Health Sciences Centre | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04824222 | Apr 2021 → Jul 2022 | COVID-19 | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07038226 | Oct 2023 → Apr 2025 | Parkinson disease, constipation disorder | Kyung Hee University Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03948919 Comparator | Jul 2019 → Nov 2023 | ulcerative colitis | University of Minnesota | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02318992 Comparator | Aug 2013 → Apr 2018 | Clostridium difficile colitis | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03183869 Comparator | Aug 2017 → Nov 2018 | relapsing-remitting multiple sclerosis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded |
| Phase 2 | NCT04434872 Comparator | Jul 2015 → Jul 2016 | ulcerative colitis | Tel-Aviv Sourasky Medical Center | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fecal Microbiota | “Oral capsules of lysophilized fecal microbiota” NCT07038226 ↗11“12 weeks of Fecal Microbiota (FM)” NCT04132427 ↗ |
| Known as | Human fecal microbiota | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04824222 ↗ |
| Action | Restore | “The goal of FMT is to introduce or restore a stable microbial community in the gut by transplanting intestinal microbiota from a healthy donor to the patient.” NCT03281044 ↗ |
| Modality | Other / unclassified | “fecal microbiota drug substance” NCT03281044 ↗ |
| Route | Oral | “capsules that are administered by the oral route” NCT02127398 ↗ |